There are companies actively developing retinal scanning technology with AI diagnosis for Alzheimer’s disease, but most are at the research or early commercialization stage and are not yet widely available to the public.
- RetiSpec is a Toronto-based company that has developed an AI-driven retinal imaging system specifically aimed at the early detection of Alzheimer’s disease by identifying amyloid proteins in the retina. Their technology uses hyperspectral imaging and AI algorithms and is currently available for research use only, as it awaits regulatory approval in both the U.S. and Canada.
- i-Cognitio Sciences (in collaboration with Humansa in Hong Kong) offers a brain health service using AI-powered retinal scans to predict Alzheimer’s disease risk. Their technology is reported to be available as part of a brain health service package in Hong Kong, but details on U.S. availability are not yet clear.i-Cognitio Sciences
- Optina Diagnostics and Imagia (Canada) are also mentioned as companies working on similar retinal AI diagnosis technologies, likely focused on early-stage detection and research partnerships.